The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.
Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, Delgado J, Kuss BJ, Tam CS, Gasztonyi Z, Offner F, Lunin S, Bosch F, Davids MS, Lamanna N, Jaeger U, Ghia P, Cymbalista F, Portell CA, Skarbnik AP, Cashen AF, Weaver DT, Kelly VM, Turnbull B, Stilgenbauer S.
Flinn IW, et al. Among authors: cashen af.
Blood. 2018 Dec 6;132(23):2446-2455. doi: 10.1182/blood-2018-05-850461. Epub 2018 Oct 4.
Blood. 2018.
PMID: 30287523
Free PMC article.
Clinical Trial.